The mifepristone safety study launched by the FDA in April 2026 is actively collecting high-quality real-world data to determine whether the current Risk Evaluation and Mitigation Strategy (REMS) program still strikes the right balance between clinical benefits and potential harms. S...

HIV prevention access strategies have reached a pivotal moment in South Africa with the imminent launch of lenacapavir, a long-acting injectable administered twice yearly. This coordinated effort directly confronts the country’s immense HIV burden, including 7.8 million people living with the vir...

New research exposes a deepening divide in cancer productivity Asia-Pacific, where middle-income countries face rapidly escalating productivity losses from premature cancer deaths and disability, while high-income economies have begun to stabilise their burdens. Between 2010 and 2022, indirect ec...

Generative AI diagnosis is stepping into neurology with striking results. In a new study, ChatGPT-4o reached 65.5% accuracy for the correct leading diagnosis in challenging polyneuropathy cases, statistically matching non-specialist neurologists (63%) while trailing specialists (74%). The model o...

Tuberculosis counselling incentives that combine conditional cash transfers with structured pre- and post-test counselling are proving highly effective at overcoming socioeconomic barriers to treatment adherence. This integrated strategy reduces long-term disease transmission while requiring only...

Mirvetuximab ovarian cancer treatment has taken a major step forward after NICE recommended mirvetuximab soravtansine for adults with folate receptor-alpha positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three...